Traws Pharma, Inc. (TRAW)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 2,733 | 57 | 57 | 57 |
| Research and development asset acquired other than through business combination, writeoff | - | - | - | 117,464 |
| Research and development | 2,291 | 2,506 | 5,113 | 3,964 |
| General and administrative | 1,691 | 2,754 | 3,480 | 1,977 |
| Total operating expenses | 3,982 | 5,260 | 8,593 | 123,405 |
| Loss from operations | -1,249 | -5,203 | -8,536 | -123,348 |
| Change in fair value of warrant liability | -146 | -26,513 | - | - |
| Other income, net | 188 | 180 | 61 | 205 |
| Net (loss) income | -915 | 21,490 | -8,475 | -123,143 |
| Net (loss) income attributable to series c preferred stockholders, basic | -290 | 6,407 | - | - |
| Net (loss) income attributable to common stockholders, basic | -625 | 15,083 | -8,475 | -123,143 |
| Earnings per share, basic | -0.11 | 2.17 | -8.81 | -4.87 |
| Earnings per share, diluted | -0.11 | 2.09 | -8.81 | -4.87 |
| Weighted average number of shares outstanding, basic | 5,820,903 | 6,965,927 | 961,530 | 25,310,774 |
| Weighted average number of shares outstanding, diluted | 5,820,903 | 7,215,125 | 961,530 | 25,310,774 |